Quantcast

Lurbinectedin (PM01183)


#1

Noteworthy, 2 synovial sarcoma patients participated in the phase 1 trial of Lurbinectedin (PM01183). Results just came out. The 2 synovial sarcoma patients had stable disease for more than 4 months with this drug. Only one of them was given the recommended dose. One of them had tried trabectedin prior to entering this trial with no success (progressive disease). The other patient had tried sorafenib but didn't achieve stable disease for as long.

There is another phase 1 trial for this drug with a different dose/schedule and is still recruiting:

http://clinicaltrials.gov/ct2/show/NCT01405391


#2

That is very good news, Elodie. Thank you for posting it. May there be further advances in the near future!


#3

The following study suggests that Lurbinectedin impacts the tumor microenvironment in a positive way: